Thermo Fisher Reports Strong Q4 2024 Earnings Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy TMO?
Source: Yahoo Finance
- Significant Revenue Growth: Thermo Fisher achieved $11.4 billion in revenue for Q4 2024, marking a 5% year-over-year increase, indicating strong performance across all markets and further solidifying its market share.
- Adjusted EPS Increase: Adjusted earnings per share rose by 8% to $6.10, reflecting the company's success in cost management and operational efficiency, which enhances investor confidence.
- Innovative Product Launches: The company launched several new products in 2024, including the Thermo Scientific Stellar mass spectrometer and Dionex Inuvion ion chromatography system, further strengthening its market leadership in biopharma and environmental testing.
- Capital Return Strategy: Thermo Fisher returned $4.6 billion to shareholders through stock buybacks and dividends in 2024, demonstrating strong cash flow and commitment to shareholders while laying the groundwork for future M&A activities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 468.040
Low
580.00
Averages
658.89
High
750.00
Current: 468.040
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Thermo Fisher Sells Microbiology Business for $1.075 Billion
- Transaction Value: Thermo Fisher has agreed to sell its microbiology business for approximately $1.075 billion in cash and a $50 million seller note, which will provide significant cash inflow but also means losing a business that generated $645 million in revenue.
- Business Impact: The microbiology unit focuses on antimicrobial susceptibility testing and culture media solutions, and while the deal is expected to close in the second half of 2026, it will dilute Thermo Fisher's adjusted earnings per share by $0.15, indicating a short-term decline in profitability.
- Market Reaction: Following the announcement, Thermo Fisher's premarket stock price dipped 0.12% to $469.12, yet the market remains optimistic about its future revenue outlook, projecting adjusted EPS between $24.64 and $25.12 for 2026.
- Strategic Shift: This transaction signifies Thermo Fisher's strategic shift towards focusing on its core business and optimizing its asset portfolio, which is expected to provide greater flexibility for future growth opportunities and competitive positioning in the market.
See More
Thermo Fisher Sells Microbiology Business for $1.08 Billion
- Transaction Value: Thermo Fisher Scientific has agreed to sell its microbiology business to pan-European private equity firm Astorg for approximately $1.08 billion, which includes cash and a $50 million seller note, providing the company with liquidity to support other strategic investments.
- Business Restructuring: This sale represents a strategic move by Thermo Fisher to optimize its business portfolio, aiming to concentrate resources on areas with higher growth potential, thereby enhancing overall operational efficiency and market competitiveness.
- Market Reaction: The market has reacted positively to this transaction, with analysts believing that this move will help Thermo Fisher achieve better growth in future financial performance, particularly in investments within the biotechnology and life sciences sectors.
- Private Equity Involvement: Astorg's participation as the buyer indicates ongoing interest from private equity firms in the microbiology sector, with expectations that they will leverage their expertise to drive further development and expansion of the business.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
JP Morgan Lowers Target Price for Thermo Fisher Scientific Inc. to $600 from $710
- Target Price Adjustment: JP Morgan has reduced its target price for Thermo Fisher Scientific from $710 to $600.
- Market Impact: This adjustment reflects changes in market conditions and expectations for the company's performance.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
Thermo Fisher Sells Microbiology Business for $1.075 Billion
- Transaction Value: Thermo Fisher has agreed to sell its microbiology business for approximately $1.075 billion in cash and a $50 million seller note, which will provide significant cash inflow but also means losing a business that generated $645 million in revenue.
- Business Impact: The microbiology unit focuses on antimicrobial susceptibility testing and culture media solutions, and while the deal is expected to close in the second half of 2026, it will dilute Thermo Fisher's adjusted earnings per share by $0.15, indicating a short-term decline in profitability.
- Market Reaction: Following the announcement, Thermo Fisher's premarket stock price dipped 0.12% to $469.12, yet the market remains optimistic about its future revenue outlook, projecting adjusted EPS between $24.64 and $25.12 for 2026.
- Strategic Shift: This transaction signifies Thermo Fisher's strategic shift towards focusing on its core business and optimizing its asset portfolio, which is expected to provide greater flexibility for future growth opportunities and competitive positioning in the market.
See More
Thermo Fisher Sells Microbiology Business for $1.08 Billion
- Transaction Value: Thermo Fisher Scientific has agreed to sell its microbiology business to pan-European private equity firm Astorg for approximately $1.08 billion, which includes cash and a $50 million seller note, providing the company with liquidity to support other strategic investments.
- Business Restructuring: This sale represents a strategic move by Thermo Fisher to optimize its business portfolio, aiming to concentrate resources on areas with higher growth potential, thereby enhancing overall operational efficiency and market competitiveness.
- Market Reaction: The market has reacted positively to this transaction, with analysts believing that this move will help Thermo Fisher achieve better growth in future financial performance, particularly in investments within the biotechnology and life sciences sectors.
- Private Equity Involvement: Astorg's participation as the buyer indicates ongoing interest from private equity firms in the microbiology sector, with expectations that they will leverage their expertise to drive further development and expansion of the business.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
JP Morgan Lowers Target Price for Thermo Fisher Scientific Inc. to $600 from $710
- Target Price Adjustment: JP Morgan has reduced its target price for Thermo Fisher Scientific from $710 to $600.
- Market Impact: This adjustment reflects changes in market conditions and expectations for the company's performance.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
